Condition
Hypertension
7 compounds were checked against hypertension, and every one of them earned a row.
Last updated
Compounds with a graded row
Ordered by rung, strongest first. The rung rates the study design; the chip beside it says what the study measured. Both are needed.
-
Adrenomedullin
human RCT Direct outcome Not approved for this condition
- Who was studied
- men aged 39-58 with uncomplicated essential hypertension, baseline 147/96 mmHg, n=8; two-hour infusions in a placebo-controlled crossover
Blood pressure was measured in hypertensive men during intravenous adrenomedullin: the high dose (5.8 pmol/kg/min for 2 hours) lowered systolic by 24.6 mmHg and diastolic by 21.9 mmHg against vehicle, with a rise in heart rate and cardiac output. This is an acute infusion study of an endogenous peptide, not a treatment course; no trial of repeated or oral administration for hypertension is on file.
Source PubMed 1 primary source read for this row
-
Apelin
human RCT Direct outcome Not approved for this condition
- Who was studied
- chronic heart failure patients NYHA II-III (n=18), patients undergoing diagnostic coronary angiography (n=6) and healthy volunteers (n=26); hypertension status of participants is not reported and no hypertensive cohort was enrolled
Mean arterial pressure was measured in humans during systemic infusion of (Pyr1)apelin-13 in a randomised, double-blind, placebo-controlled study and fell in both heart failure patients and healthy controls, with peripheral and coronary vasodilatation and a rise in cardiac output. The trial was designed around heart failure: no hypertensive population was studied, and the infusions were acute, lasting minutes.
Source PubMed 1 primary source read for this row
-
Atrial Natriuretic Peptide (ANP)
human RCT Direct outcome Not approved for this condition
- Who was studied
- patients with essential hypertension, n=6, single intravenous injection; normotensive volunteers studied for comparison
Arterial pressure was measured in humans after a 100 microgram intravenous injection of alpha-human atrial natriuretic peptide in a double-blind, placebo-controlled study: pressure fell within 2 minutes and had returned to placebo levels by 10 minutes, while urinary sodium excretion rose sixfold over 30 minutes. The blood pressure effect in the hypertensive patients was less sustained than the renal effect, and no trial of ANP given for the ongoing treatment of hypertension is on file.
Source PubMed 1 primary source read for this row
-
Soy Peptides
human RCT Direct outcome Not approved for this condition
- Who was studied
- adults with untreated systolic 130-159 mmHg and/or diastolic 80-99 mmHg (prehypertension to stage 1 hypertension), n=100, 8 weeks
Office blood pressure was measured in humans: 4.5 g of black soy peptides daily for 8 weeks was followed by a systolic fall of -9.69 +/- 12.37 mmHg against -2.91 +/- 13.29 mmHg on placebo, alongside changes in malondialdehyde, superoxide dismutase and nitric oxide. The enrolled population was hypertensive rather than normotensive. No regulator has approved soy peptides for hypertension.
Source PubMed 1 primary source read for this row
-
Angiotensin (1-7)
human case series Surrogate marker Not approved for this condition
- Who was studied
- patients with essential hypertension (n=8) and normotensive controls (n=8); intra-arterial infusion into the brachial artery, 5 minutes per dose, not randomised and not placebo-controlled
What was measured was forearm blood flow by venous occlusion plethysmography, which rose dose-dependently by about 32% in the hypertensive patients and about 29% in the controls; systemic blood pressure was not the outcome, and a local vasodilator response in one limb is not a blood pressure result. No study on file measured office, ambulatory or home blood pressure in people given angiotensin-(1-7).
Source PubMed 1 primary source read for this row
-
Neurotensin
animal in vivo Direct outcome Not approved for this condition
- Who was studied
- anaesthetised normotensive rats; intrathecal administration, 0.5 micromolar to 3 millimolar, acute recording only
Mean arterial pressure was measured directly in anaesthetised rats and fell dose-dependently, to about -25 mmHg at 3 mM, with bradycardia and reduced sympathetic nerve activity. The animals were normotensive and the peptide was placed into the intrathecal space rather than given systemically, so this is spinal cardiovascular physiology; no study measured blood pressure in a hypertensive animal model or in any human given neurotensin.
Source PubMed 1 primary source read for this row
-
Wheat Peptides
animal in vivo Direct outcome Not approved for this condition
- Who was studied
- spontaneously hypertensive rats; group sizes, dose and dosing duration are not stated in the abstract and the full text is paywalled
Systolic, diastolic and mean arterial pressure were measured in living spontaneously hypertensive rats and fell after wheat oligopeptides; the same paper reports 77% ACE inhibition at 2.5 mg/mL in a test tube, which is a separate in vitro result. No study measuring blood pressure in humans given wheat-derived peptides was located: the registered trial NCT02197910 posted no results and no publication was found, so the human blood-pressure claim remains a named gap and this row is rat evidence only.
Source PubMed 1 primary source read for this row
Every compound checked earned a row
Nothing was checked against hypertension and set aside. That is unusual — most conditions here have a list at the bottom of this page.
What this page does not say
It reports what was measured, in whom, and how directly. It does not say what to take or at what dose, and a row here is a record of a study rather than a reason to use anything. Every rung links to the rubric that assigned it.